PTC Therapeutics Acquires Assets from Sangamo Therapeutics for Gene Therapy Product
Acquiring Company
PTC Therapeutics
Acquired Company
Sangamo Therapeutics
South PlainfieldBrisbaneBiotechnologyBiotechnologyHealth CareGeneticsTherapeuticsDescription
On August 25, 2026, PTC Therapeutics, Inc. entered into an asset purchase agreement with Sangamo Therapeutics, Inc. to acquire assets primarily related to ST-920, a gene therapy candidate for Fabry disease. The acquisition includes an upfront payment of $111 million, with potential additional milestone payments of up to $100 million. PTC will also assume specified liabilities of Sangamo as part of the agreement. This acquisition is aimed at advancing PTC’s capabilities in gene therapy.
Don't miss PTC Therapeutics's next move
Get an email the moment PTC Therapeutics makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Sangamo Therapeutics?
Sangamo Therapeutics was acquired by PTC Therapeutics, based in South Plainfield. The deal was reported on August 28, 2026. PTC Therapeutics is a biopharmaceutical company that engages in the discovery, development and commercialization of small-molecule drugs. PTC Therapeutics is publicly traded (PTCT) and operates in Biotechnology.
When did PTC Therapeutics acquire Sangamo Therapeutics?
PTC Therapeutics's acquisition of Sangamo Therapeutics was reported on August 28, 2026. On August 25, 2026, PTC Therapeutics, Inc. entered into an asset purchase agreement with Sangamo Therapeutics, Inc. to acquire assets primarily related to ST-920, a gene therapy candidate for Fabry disease. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Sangamo Therapeutics do?
Sangamo Therapeutics, Inc. is a genomic medicine company based in California. It is publicly traded (SGMOQ), operating in Biotechnology, and is based in Brisbane.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.